Literature DB >> 18799853

Osteoclastogenesis--current knowledge and future perspectives.

M P Yavropoulou1, J G Yovos.   

Abstract

The strength and integrity of the human skeleton depends on a delicate equilibrium between bone resorption by osteoclasts and bone formation by osteoblasts. This equilibrium is continuously compromised by a variety of genetic, humoral, and mechanical alterations. In osteoporosis, this balance shifts in favor of osteoclasts, and bone resorption exceeds bone formation. More detailed knowledge of the biology of osteoclasts and osteoclastogenesis has shown that the involved procedures can provide opportunities for developing therapeutic agents. Osteoclastogenesis is a multi-complex procedure that includes many stages, and each one of them presents as a potential target for therapeutic intervention, except for the stage of commitment of pre-osteoclasts,at least for the time being. Because the osteoclast is derived from the pluripotent hematopoietic stem cell, any intervention in this stage could result in serious adverse effects from the hematopoietic system. On the contrary, intervention in the later stages of differentiation, multi-nucleation, and activation, has proved to be very promising in the development of novel potent anti-resorptive agents. In the present review we summarized the current knowledge related to osteoclast differentiation and the new developing targets of pharmacological intervention in each stage of this extremely complicated and not completely elucidated process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799853

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  66 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.

Authors:  Simone Reuter; Subash C Gupta; Kanokkarn Phromnoi; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Takashi Nishida; Kenji Emura; Satoshi Kubota; Karen M Lyons; Masaharu Takigawa
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

4.  RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Authors:  Antonio Garcia-Gomez; Enrique M Ocio; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Invest New Drugs       Date:  2012-07-07       Impact factor: 3.850

5.  Activating transcription factor 4 regulates osteoclast differentiation in mice.

Authors:  Huiling Cao; Shibing Yu; Zhi Yao; Deborah L Galson; Yu Jiang; Xiaoyan Zhang; Jie Fan; Binfeng Lu; Youfei Guan; Min Luo; Yumei Lai; Yibei Zhu; Noriyoshi Kurihara; Kenneth Patrene; G David Roodman; Guozhi Xiao
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

Review 6.  Modulation of osteoclast differentiation and bone resorption by Rho GTPases.

Authors:  Heiani Touaitahuata; Anne Blangy; Virginie Vives
Journal:  Small GTPases       Date:  2014-03-10

7.  Disruption of the transcription factor RBP-J results in osteopenia attributable to attenuated osteoclast differentiation.

Authors:  Jing Ma; Ya-Li Liu; Yi-Yang Hu; Ya-Ning Wei; Xing-Cheng Zhao; Guang-Ying Dong; Hong-Yan Qin; Yin Ding; Hua Han
Journal:  Mol Biol Rep       Date:  2012-12-07       Impact factor: 2.316

8.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.

Authors:  Ilaria Roato; Francesco Porta; Alessandro Mussa; Lucia D'Amico; Ludovica Fiore; Davide Garelli; Marco Spada; Riccardo Ferracini
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone.

Authors:  Yuanqing Huang; Ning Chen; Dengshun Miao
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.